Dr. Prashant Joshi

Bio

Dr. Prashant Joshi is an accomplished researcher and academician in the field of medicinal chemistry, specializing in natural product-based drug discovery. He earned his B. Pharm. from Mahakal Institute of Pharmaceutical Sciences, Ujjain (India) in 2006, followed by an M. Pharm. from the School of Pharmaceutical Sciences, RGPV Bhopal (India) in 2009. In 2018, he obtained his Ph.D. under the supervision of Dr. Sandip B. Bharate at CSIR-Indian Institute of Integrative Medicine, Jammu (India), through the Academy of Scientific and Innovative Research (AcSIR), New Delhi, as a CSIR-Senior Research Fellow. Dr. Joshi has held academic positions in pharmaceutical and natural product chemistry departments at SPTM, NMIMS Shirpur. Currently, he serves as an Associate Professor at the School of Health Science and Technology, Dr. Vishwanath Karad MIT World Peace University, Pune, India. His research interests focus on medicinal chemistry and natural products, aiming to discover new therapeutics for multi-drug-resistant (MDR) cancers and bacterial infections. He has an impressive record of 32 research publications and 9 US patents granted in the field of natural source-based drug discovery.

Educational Qualifications
M. Pharm, PhD

Area of Expertise
Drug design and discovery in oncology
Isolation and characterization of natural products
Molecular modeling and MD simulations
Infectious diseases and Multidrug resistance

Recent Publications

Identification of Potent and Selective CYP1A1 Inhibitors via Combined Ligand and Structure-Based Virtual Screening and Their in Vitro Validation in Sacchrosomes and Live Human Cells. J. Chem. Inf. Model. 2017, 57, 6, 1309–1320.

A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis. Mini Rev Med Chem 2024;24(6):571-587.

Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer . Eur. J. Med. Chem. 2017 138, 273-292

Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy via screening of a natural product repository. MedChemComm. 2018, 9, 2, 371-378

Pharmaceutical composition for the treatment of multi-drug resistant infections. US Patent 10,064,840.

Osthol and curcumin as inhibitors of human Pgp and multidrug efflux pumps of Staphylococcus aureus: Reversing the resistance against frontline antibacterial drugs. MedChemComm. 2014, 5, 1540-1547.

Google Scholar Link
https://scholar.google.co.in/citations?hl=en&user=U5dErZIAAAAJ&view_op=list_works&sortby=pubdate

Scopus Author ID link
https://www.scopus.com/authid/detail.uri?authorId=55346059500

Orcid Link
https://orcid.org/0000-0002-2513-1969